Pharmacological personalization of JAK inhibitors in rheumatoid arthritis: A multi-omics and AI-based scoping review and evidence-gap map.
Current multi-omics and AI/ML evidence is insufficient to guide routine selection of a specific JAK inhibitor in rheumatoid arthritis and a "data × methods × JAKi" map identifies both emerging signals and the links that must be strengthened before MO/MM and AI/ML can support clinical decision-making in RA.